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Abstract
Purpose: The aim of the current investigation was to calibrate the diode in-vivodosimetry (IVD) system for high-dose-rate (HDR) brachytherapy and to design aphantom study for in-vivo dosimetry of HDR brachytherapy applicators. Methods:Gamma Med Plus with Abacus 3.1 treatment planning system (TPS), and diodedosimetry system has been used in this study. Calibration and different correctionfactors of diode have been measured in water phantom. Treatment simulation,planning of different applicators for esophagus, rectum/vagina and cervix (fletcher& ring), dose delivery and finally in-vivo verification at prescription point usingdiode in water phantom has been performed. Results: The mean calibration factorfor diode for Ir-192 HDR source is 1.256 (N=15) with σ ± 0.0015. The overallaverage percentage difference between TPS dose and diode dose was 1.87% (σ ±2.64) for all measurements, 1.86% (σ ± 2.73) for esophagus, 1.86% (σ± 2.94) forrectum/vagina and 1.67% (σ ±2.81) for fletcher and 2.07% (σ ± 2.26) for ringapplicators, respectively. These results advocate that the dose calculated by TPSand dose measured using diode for the various clinical situations deliberated hereare in good agreement (~2%) at the points of clinical importance. Conclusion: Thein-vivo phantom dosimetry study gives both a confidence that the treatments arebeing delivered as prescribed and enhance the reliability of the HDR brachytherapytreatment. This may be used for acceptance testing/commissioning of newtreatment planning system and to validate the new brachytherapy techniques inthe clinics.
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1. IntroductionBrachytherapy is a vital part of radiotherapy for thetreatment of malignancies and is frequently used withexternal beam radiation therapy (EBRT) forradical/palliative treatment. Several studies havesuggested that control rates are considerably enhancedwith EBRT and brachytherapy.1,2 HDR remote afterloading brachytherapy has been  commonly used allover the world.2 Radiation therapy is a chain likeprocedure. The ambiguity in each step may influence theaccuracy of subsequent steps and, therefore can have animpact on the overall treatment results. Accuracy ofdose delivery of HDR brachytherapy may be contributedto the success of aims of treatment, improve tumor
control and lessened toxicity of normal tissue and is achallenging task in brachytherapy due to smalltreatment depths, steep dose gradients and largedifference in absorbed dose in volumes of concern.In recent past, a number of unwanted radiationincidents, which seriously affect the treatmentobjectives were noted in different countries.3-7Thomadsen et al. recognized 44 errors in HDRbrachytherapy treatment in data (1980-2001) from theNuclear Regulatory Commission and InternationalAtomic Energy Agency.8 IAEA Safety Report Series No179 conferred 32 incidents involving brachytherapy,
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ICRP 8610 identified potential errors in brachytherapyescalating from problems with equipment, calibration,treatment planning, and treatment delivery and ICRP9711 described over 500 accidents involving HDRbrachytherapy. Those events highlighted the need ofmore accurate dose delivery to the patient undergoingbrachytherapy. IVD is the measurement of radiationdoses to patients undergoing brachytherapy in order toguarantee that the treatments are delivered as planned.IVD is recommended by the World Health Organization(WHO)12, the International Commission on RadiologicalProtection (ICRP) 10, the International Atomic EnergyAgency (IAEA)13 and other bodies like AmericanAssociation of Physicists in Medicine (AAPM) 14 andEuropean Society for Therapeutic Radiology andOncology (ESTRO)15 for routine verification of the dosedelivery for all groups of patients undergoingradiotherapy.The significance of independent verification ofdosimetry earlier to HDR brachytherapy treatmentdelivery by a simple method has been acknowledgeduniversally and a significant literature is available16-21but these are not the alternate to the IVD. The need ofpatient-specific QA as well as independent verification ofthe planned dose are obvious22-23 and have to beperformed to ensure the safety and accuracy of thetreatment dose delivery. Diode is used since it offerreal-time response, high sensitivity, better spatialresolution, robustness, absence of bias voltage, etc. andit is available almost in every radiation therapydepartment.Regarding in-vivo dosimetry in HDR brachytherapy,literature is available on verification of dose at organs atrisk (bladder & rectum) 24-29 but no literature was foundon verification of absorbed dose at prescription point.The key objective of the current investigation is toperform a phantom study similar to clinical setup andverify the absorbed dose in HDR brachytherapy at theprescription point. The dose verification is made withdiode and it is based on the postulation that thecovenant between the measured and calculated dose insetup that really mimics the clinical situations impliesthat the dose delivered to the target volume is theanticipated dose.
2. Methods and MaterialsMeasurements have been performed using photonsource of Ir-192 for a HDR Gamma Med Plus (VarianMedical solution, USA) machine. The source has beencalibrated using a well ionization chamber dosimetrysystem (HDR 1000 Plus, Sr. No. A040623 & ElectrometerCDX-2000B, Sr. No. J033533 Standard Imaging, USA)).30The IVD system used in this study consist of PDM ModelNo. 37-721(electrometer, Nuclear Associates, NY, USA)and ISORAD n-type diode (9731-0 for 70-all energies i.e.energy compensated, Nuclear Associates, NY, USA). A
3-D water phantom (60×55×50-cm, Model 9750, Sr. No.20075001, Multidata Systems International Corp., USA)has been used for the calibration of the IVD system. Thediode IVD system has been calibrated as perrecommended procedure in literature.13 Diode has beenplaced in a 2 cm rectum cylinder filled with water andsource catheter has been taped onto the surface ofcylinder, center-to-center distance of 1 cm13 and thewhole assembly has been put in water phantom forcalibration as shown in Figure 1a. A dose of 5 Gy hasbeen delivered for calibration of diode IVD system at 1cm center-to-center distance between diode and thedwell position, using the current strength of Ir-192 HDRsource. Correction factors that are relevant to clinicaluse have been measured. The dependence of diodesignal on distance has been measured at 1-5 cm with 1cm interval, the arrangements are shown in Fgure 1b. Adose of 50 cGy has been delivered at each position. Thedirectional dependence of the diode has been measuredby placing the diode in center of after loading cylindricalPMMA phantom and source at 00, 900, 1800, and 2700angles and then replace the position of the diode withthe source as shown in Figure 1c & d. The temperatureeffect on diode was not investigated, since allmeasurements and calibration have been performed inwater phantom at room temperature. If the first threereadings were identical, it was taken as the average, ifnot the case; the average of five readings was used.The diode and applicator (for esophagus, rectum/vaginaand cervix) have been fixed at prescription treatmentdepth. The whole assembly has been put in the waterphantom in position that mimics the clinical condition.Simulation has been performed for the above mentionedassembly and a radiograph has been taken shown inFigure 1e-h to reconstruct the position of diode andapplicator in the TPS. Treatment planning has beenperformed using Abacus 3.1 TPS. Finally the treatmenthas been delivered and diode reading has been taken tocalculate the delivered dose as shown in Figure 1i-l.The dose from diode signal has been calculated using thefollowing equation;D= (Rdiode) (NIr-192) (Kdirection) (Kdistance)where, D is the diode dose; Rdiode is the diode signal;NIr-192 is the calibration factor; kdirection is the directiondependence correction factor and kdistance is the distancecorrection factor. Then TPS and diode doses have beencompared.All dosimetric calculations have been performed for anominal 37 GBq (10 Ci) source strength using ABACUS3.1 (TPS, manufactured by Varian Medical Solutions,USA) and 5 Gy as prescribed doses at 0.4 cm depth awayfrom the esophagus applicators, at 0.5 cm depth fromrectum/vaginal applicators and 7 Gy dose at point A forfletcher/ring applicators. Treatment planning for
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brachytherapy using different available applicators wasaimed to be verified with the IVD system. The dose hasbeen measured at second, central and second lastposition for esophagus and rectum/vagina applicatorsand at point A (left & right) for fletcher & ringapplicators and then average dose has been taken.
The applicators available at BINO for esophagus,rectum/vagina and cervix (fletcher & ring)manufactured by Varian Medical Solution, USA and arecompatible with Gamma Med plus HDR unit and Abacus3.1 TPS have been used for this study. MS Excels, SPSS16.0 have been used for data analysis. EndNote 5 hasbeen used for reference management.
Figure 1: The setup for (a) calibration, (b) distance correction factor, (c) & (d) angle correction factor determination hasbeen shown. The simulation films for (e) esophagus, (f) rectum/vagina, (g) fletcher and (h) ring applicators as well as diodeare shown. The measurements arrangements for (i) esophagus, (j) rectum/vagina, (k) fletcher and (l) ring applicators anddiode are shown in water phantom.
Table 1: Correction factors for diode in-vivo dosimetry system.Diode at center Source at center Distance between center of sourceand diodePosition Rdiode Kdirection Rdiode Kdirection Distance (cm) Rdiode Kdistance00 7.4 1.00 7.40 1.00 1 30.7 1900 7.4 1.00 7.4 1.00 2 31.2 0.9841800 7.5 0.99 7.5 0.99 3 31.7 0.9682700 7.4 1.00 7.3 1.01 4 32.3 0.950
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3. ResultsThe aim was to characterize the diode for HDRbrachytherapy treatment and finally to verify theabsorbed dose calculated by TPS at prescription pointusing diode for different HDR brachytherapyapplicators. The calibration factor has been measured ondaily basis for fifteen days to check the consistency ofthe in-vivo dosimetry system. The calibration factordoes not change significantly over the period of studyand a good consistency has been observed. The meancalibration factor for diode for Ir-192 HDR source is1.256 (N=15) with standard deviation ± 0.0015. Thedistance correction factor has been measured as persetup shown in Figure 1b and from 1-5-cm distance with1 cm increment. The mean distance correction factor is0.968 with standard deviation ± 0.026. The directionaleffect has been measured as per arrangements shown inFigure 1c & d. The mean directional effect is 0.998 withstandard deviation ± 0.005 and 1.00 with standarddeviation ± 0.008 for diode and source in the centerrespectively. The directional and distance correctionfactors for diode are presented in Table 1.
The absorbed dose at prescription point has beenmeasured for different applicators available foresophagus, rectum/vagina, and cervix with diode IVDsystem in water phantom that mimics the clinical setup.The percentage difference between the TPS dose anddiode dose has been calculated for different HDRbrachytherapy applicators available for esophagus,rectum/vagina and cervix (fletcher & ring) and resultsare presented in the tables 2-5.The data in the tables shows that the overall averagepercentage difference between TPS dose and diode dosewas 1.87% (standard deviation ± 2.64) for allmeasurements, 1.86% (standard deviation ± 2.73) foresophagus, 1.86% (standard deviation ± 2.94) forrectum/vagina and 1.67% (standard deviation ±2.81)for fletcher and 2.07% (standard deviation ± 2.26) forring applicators, respectively.These results advocate that the dose calculated by TPSand dose measured using diode for the various clinicalsituations deliberated here are in good agreement (~2%) at most of the points of clinical importance.
Table 2: In-vivo phantom results for various diameter esophagus HDR brachytherapy applicators.Applicatordia (cm) TreatmentLength (cm) TreatmentDepth (cm) TPS Dose(cGy) DiodeDose (cGy) %Difference0.80 4 0.30 500 504.70 -0.946 0.30 500 485.30 2.948 0.30 500 491.70 1.661.00 4 0.30 500 490.30 1.946 0.30 500 506.30 -1.268 0.30 500 478.50 4.301.20 4 0.30 500 475.90 4.826 0.30 500 508.60 -1.728 0.30 500 476.80 4.641.40 4 0.30 500 477.10 4.586 0.30 500 511.30 -2.268 0.30 500 481.60 3.68
Table 3: In-vivo phantom results for various diameter rectum/vagina HDR brachytherapy applicators.Applicatordia (cm) TreatmentLength(cm) TreatmentDepth (cm) TPS Dose(cGy) DiodeDose (cGy) %Difference2.00 2 0.50 500 491.30 1.743 0.50 500 511.30 -2.264 0.50 500 475.10 4.982.30 2 0.50 500 493.20 1.363 0.50 500 506.30 -1.264 0.50 500 470.20 5.962.60 2 0.50 500 481.40 3.723 0.50 500 513.40 -2.684 0.50 500 483.80 3.243.00 2 0.50 500 476.30 4.743 0.50 500 509.30 -1.864 0.50 500 481.60 3.683.50 2 0.50 500 482.80 3.443 0.50 500 479.50 4.104 0.50 500 505.40 -1.08
Volume 4 • Number 4 • 2016                                               International Journal of Cancer Therapy and Oncology 5
www.ijcto.org
© Gadhi et al. ISSN 2330-4049
Table 4: In-vivo phantom results for various length and angle tandem fletcher HDR brachytherapy applicators.TandemLength(cm) TandemAngle (00) PrescriptionPoint TPS Dose(cGy) Diode Dose(cGy) %Difference2.00 30 A 700 680.10 2.8445 A 700 710.30 -1.4760 A 700 673.60 3.774.00 30 A 700 715.30 -2.1945 A 700 664.50 5.0760 A 700 670.10 4.276.00 30 A 700 711.70 -1.6745 A 700 691.30 1.2460 A 700 676.60 3.34
Table 5: In-vivo phantom results for various length and angle tandem ring HDR brachytherapy applicators.TandemLength (cm) TandemAngle (00) PrescriptionPoint TPS Dose(cGy) DiodeDose (cGy) % Difference2.00 30 A 700 711.90 -1.7045 A 700 671.80 4.0360 A 700 683.20 2.404.00 30 A 700 685.10 2.1345 A 700 668.90 4.4460 A 700 678.20 3.116.00 30 A 700 711.70 -1.6745 A 700 682.70 2.4760 A 700 675.80 3.46
4. DiscussionThough a sufficient literature is available on diodein-vivo dosimetry however mostly for external beamradiotherapy and some investigators focused on rectumdose verification for gynecological HDR brachytherapy
25-27,31 yet no literature was found on directmeasurement of dose at prescription point. In thepresented study, an in-vivo phantom study has beendesigned to simulate the clinical situation forverification of dose at prescription point for HDRbrachytherapy. Treatment planning is a complex as wellas a time taking process in radiotherapy in general andin brachytherapy in particular that includes theapplicator insertion, a complex simulation, CT/MRI orOrthogonal radiograph, transfer of simulation data totreatment planning system and then the best possibletreatment plan for an individual patient. Each step isprone to one or more sources of error, so it is essentialto be performed with the greatest accuracy achievable.The ambiguity in each step may influence the accuracyof subsequent steps and, therefore can have an impacton the overall treatment results. Confirmation of thedose delivery before treatment in a phantom certainlyensures the accuracy, reliability and authenticity of allcomponent processes.The calibration factor does not change significantly overthe period of study and a good consistency has beenobserved. The same effect has been observed
previously.26, 32 The angle and distance correctionfactors are insignificant and comparable to publisheddata.26A 5% difference between measured and TPS dose valuesis permissible as per International Atomic EnergyAgency (IAEA) after their coordinated project on in-vivodosimetry using MOSFET.13 The size of diode is verylarge as compared to MOSFET that increase thepossibility of more differences but most of the results(average of our results) is within the tolerance. Tables2-5 show that the dose calculated by TPS and measuredusing diode are closely matched. The phantommeasurements mimicking the actual clinical conditionsagreed with the anticipated, i.e., TPS calculated valueswithin ± 5% (standard deviation ± 2.64). Our results arecomparable to published literature. 19, 25, 26 Themaximum difference between the dose measured bydiode and calculated by TPS was 5.96%.This study may be helpful for verification of theprecision and accuracy of dose calculation at the time ofcommission/acceptance testing of TPS and, following,for periodical quality control test. Further, it can bevaluable in validating the new treatment procedures toguarantees the correctness of dose delivery and safety ofthe patients for brachytherapy treatments.
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5. ConclusionThe diode IVD system has been characterized for HDRbrachytherapy dose verification. The overall averagepercentage difference between TPS dose and diode dosewas 1.87% ± 2.64 for all measurements, 1.86% ± 2.73for esophagus, 1.86% ± 2.94 for rectum/vagina and1.67% ±2.81 for fletcher and 2.07% ± 2.26 for ringapplicators, respectively. These results revealed that thedose calculated by TPS and dose measured using diodefor the different clinical settings reflected here are ingood agreement (~2%) at most of the points of clinicalimportance. The in-vivo phantom dosimetry study givesboth a confidence that the treatment is being deliveredas prescribed and enhances the reliability of the HDRbrachytherapy treatment.
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